How Effective are Checkpoint Inhibitors in Gynecologic Cancers?
The effectiveness of checkpoint inhibitors can vary depending on several factors, including the type of cancer and the patient's overall health. Clinical trials have shown promising results, particularly for patients with certain biomarkers like PD-L1 positivity or microsatellite instability-high (MSI-H) tumors. However, more research is needed to fully understand their efficacy.
